🇺🇸 FDA

Company profile · Sponsor

Dyne

Dyne Therapeutics

DYN · NYSE pharma WALTHAM, MA, USA
Pipeline
6
Drugs
1
Patents
8

Quick answer

Dyne (DYN) is a pharma company. headquartered in WALTHAM, MA, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker DYN
Exchange NYSE
Company type pharma
Headquarters WALTHAM, MA, USA
SEC CIK 0001818794

Pipeline (6)

Search pipeline →

  1. SODIUM CHLORIDE , DYNE-101

    Dyne

    Myotonic Dystrophy Type 1

    phase 3 small molecule active

    1 trial

  2. zeleciment basivarsen (DYNE-101)

    Dyne

    Myotonic Dystrophy Type 1 (DM1)

    phase 3 small molecule active

    1 trial

  3. DYNE-101

    Dyne

    Myotonic Dystrophy Type 1 (DM1)

    phase 2 small molecule active

    1 trial

  4. DYNE-101, The placebo is commercially available 0.9% (w/v) saline solution intended for IV

    Dyne

    Myotonic Dystrophy Type 1

    phase 2 small molecule active

    1 trial

  5. DYNE-251

    Dyne

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  6. The placebo is commercially available 5% dextrose solution intended for IV, DYNE-251, DYNE-251

    Dyne

    Duchenne muscular dystrophy

    phase 2 small molecule active

    1 trial

Drugs (1)

Search drugs →

  1. propoxyphene napsylate

    DARVON-N

    ORAL approved

Patents (8)

Search patents →

  1. US 12428487

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12403203

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12397062

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12370264

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12357703

    Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12329824

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12329825

    Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12325753

    Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy

    Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Dyne?

Dyne (DYN) is a pharma company. headquartered in WALTHAM, MA, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Dyne sponsor?

We track 6 ClinicalTrials.gov-linked programs for Dyne, including SODIUM CHLORIDE , DYNE-101 and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Dyne company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.